Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030
Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

RootsAnalysis is pleased to announce the publication of its recent study, titled, “LiquidBiopsy and Other Non-Invasive Cancer Diagnostics Market, 2021-2030: Focuson Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and OtherBiomarkers.”

Liquidbiopsies have emerged as a versatile diagnostic solution, especially for caseswhen conventional (invasive) diagnostic tests are inconclusive or when theclinical condition is related to an organ that is not amenable to biopsy access

Giventhe invasive and cost-intensive nature of tissue biopsies, there is asignificant unmet need for safer and more patient-friendly cancer diagnosticsthat are capable of offering highly accurate, and actionable insights relatedto the disease.

Thefinancial opportunity within the liquid biopsy and other non-invasive cancerdiagnostics market has been analyzed across the following segments:

BrowseDetailed Report: https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

Typeof Tumor Marker

·       ctDNA

·       cfDNA

·       CTCs

·       Exosomes

·       Others

Application

·       Diagnosis / Early Diagnosis

·       Patient Monitoring

·       Recurrence Monitoring

TargetCancer Indication

·       Breast Cancer

·       Lung Cancer

·       Colorectal Cancer

·       Prostate Cancer

·       Bladder Cancer

·       Melanoma

·       Gastric Cancer

·       Pancreatic Cancer

·       Ovarian Cancer

·       Others

EndUsers

·       Hospitals

·       Research Institutes

·       Others

KeyGeographical Regions

·       North America

·       Europe

·       Asia-Pacific

·       Rest of the World

GetCustomized Report @ LiquidBiopsy and Other Non-Invasive Cancer Diagnostics Market Emerging Trends

KeyMarket Insights

·       Presently, nearly 300 non-invasive diagnostictests, designed for the detection of various types of cancers, are eitheralready available in the market or under development across the world

·       Several modern diagnostic tests claim to becapable of offering results in relatively short time periods, thereby,facilitating early diagnosis that is particularly beneficial in the treatmentof different types of cancers

·       Over time, big pharma players have initiatedproduct development programs, having invested significant capital, time andeffort, on non-invasive diagnostic solutions for use across differentoncological indications

·       Investors, having realized the untappedopportunity within this emerging segment of the cancer diagnostics market, haveinvested over USD 3 billion across 120 instances in the period between 2015 and2019

·       The growing interest in this field is alsoreflected in the partnership activity; deals inked in the recent past arefocused on a diverse range of tumor markers, involving both international andindigenous stakeholders

·       The projected future opportunity isanticipated to be driven by increasing patient population and distributedacross various disease indications and application areas across key geographies

·       These tests are capable of detecting diversetumor markers that cater to the needs of different stakeholders; in fact,opinions of industry experts confirm the vast potential of liquid biopsies indisease diagnosis / monitoring

KeyPlayers:

·       Amoy Diagnostics

·       DiaCarta

·       HaploX Biotechnology

·       NeoGenomics

·       QIAGEN

·       Swift Biosciences

·       Sysmex Inostics

·       Thermo Fisher Scientific

Tableof Contents

1. Preface

2. Executive Summary

3. Introduction

4. Non-Invasive CancerScreening and Diagnosis

5. Market Landscape

6. Company Profiles

7. Partnerships andCollaborations

8. Funding and InvestmentAnalysis

9. Liquid Biopsy:Initiatives of Big Pharma Players

10. Key Acquisition Targets

11. Other Non-InvasiveCancer Diagnostics

12. Market Sizing andOpportunity Analysis

13. Survey Insights

14. Conclusion

15. Executive Insights

16. Appendix 1: TabulatedData

17. Appendix 2: List ofCompanies and Organizations

KeyQuestions Answered

·       What are the prevalent trends within theliquid biopsy market? 

·       What are the key applications of liquidbiopsy?

·       Apart from liquid biopsy, what are the othernovel non-invasive cancer diagnostics?

·       What is the role of big pharma players in thenon-invasive cancer diagnostics domain?

·       What are the prevalent financing andinvestment trends within the liquid biopsy market?

·       What are the most popular cancer indicationsfor which non-invasive diagnostics are being developed?

·       Who are the key service providers for liquidbiopsy products?

·       How is the current and future marketopportunity likely to be distributed across key market segments?

Requestfor PDF [email protected]    LiquidBiopsy and Other Non-Invasive Cancer Diagnostics Market Analysis

AlsoVisit Our Latest Publication:

Cloud-based Solutions for Drug Discovery,Development and Manufacturing Market

CAR-T Cell Therapies Market

Patient Recruitment and Retention ServicesMarket

mRNA Therapeutics and Vaccines Market

T-Cell (CAR-T, TCR, and TIL) TherapiesMarket

AboutRoots Analysis

RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at [email protected]

ContactInformation

RootsAnalysis Private Limited

GauravChaudhary

+1(415) 800 3415

[email protected]

YOUR REACTION?


You may also like

Facebook Conversations



Disqus Conversations